A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients

Trial Profile

A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs RG 7916 (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SUNFISH
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 16 Apr 2018 According to the Genentech media release, updated pharmacodynamic and safety data from Part 1 of this trial will be presented at the 70th American Academy of Neurology (AAN) Annual Meeting 2018.
    • 27 Jan 2018 According to a PTC Therapeutics media release, updated pharmacodynamic and safety data from Part 1 of this trial were presented at the International Scientific Congress on Spinal Muscular Atrophy.
    • 26 Jan 2018 Planned End Date changed from 5 May 2020 to 16 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top